In case folks did not see this, I am posting a Press Release regarding WF10. Hopefully it will be good news.
---------------------------------------------------------------------------------------------
WF10 study completed
Dimethaid Research Inc DMX
Shares issued 33,021,526 Jan 28 close $2.95
Thu 29 Jan 98 News Release
Mr Peter Block reports
Oxo Chemie AG announced today that the Mechanism of Action Study (phase
IIb) of WF10 has recently been completed. The mechanism of WF10 pertaining
to immunosuppression will be presented at the third International
Conference on New Trends in Clinical and Experimental Immunosuppression in Geneva, Switzerland in February.
Dr Michael McGrath, head of the AIDS Immunobiology Research Laboratory at
the university of California San Francisco, has been accepted for an oral
presentation of his abstract entitled "Effect of WF10 (TCDO) on Antigen
Presentation." This will be the first scientific publication on WF10.
Dr F. W. Kuhne, president and CEO of Oxo Chemie, invented WF10. The drug is
designed to provide a significant and substantial enhancement of macrophage
function and activity. The macrophage is a large scavenger cell that
ingests degenerated cells and foreign organisms. An earlier phase II
double-blind study of people with late-stage AIDS at Vanderbilt University
Hospital appeared to demonstrate that those treated with WF10 resisted
life-threatening, opportunistic infections associated with the disease. For
example, patients in the control group experienced 53 days of
hospitalization and 110 home care days whereas those on WF10 required
neither hospitalization nor home care. In a post-study follow-up after 18
months, eight of the nine patients in the control group had died whereas
only two of ten taking WF10 had died.
Dimethaid holds a 20% interest in Oxo Chemie with an option to increase
this to 25%, as well as the Canadian distribution rights to WF10.
(c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com |
